Table 3.

Relationships between the short-term side-effects (myelosuppression, gastrointestinal toxicity and infection event) of pulsed high-dose cyclophosphamide (CTX) therapy and various covariates including gender, age, body weight, total CTX dose, and GSTM1, GSTT1 and GSTP1 genotypes in SLE patients by logistic regression analysis

Factor	Myelotoxicity		GI symptoms		Infection
	OR	95% CI	OR	95% CI	OR	95% CI
Age	1.02	0.98, 1.06	0.96	0.92, 1.01	1.00	0.95, 1.06
Gender	0.47	0.12, 1.88	0.78	0.18, 3.37	0.84	0.18, 4.07
Body weight	0.95	0.90, 1.01	0.95	0.90, 1.00	1.01	0.95, 1.08
Total dose	1.07	0.13, 9.00	0.34	0.04, 3.18	3.05	0.20, 47.75
GSTM1	1.70	0.70, 4.16	1.57	0.63, 3.93	2.91	0.84, 10.05
GSTT1	0.55	0.22, 1.37	0.82	0.33, 2.08	0.94	0.30, 2.96
GSTP1	5.75*	2.25, 14.70	3.83*	1.45, 10.08	2.48	0.80, 7.64

CI Confidence interval; GI gastrointestinal; OR = Odds ratio.

^*P < 0.05.